Integrated epigenetic and genetic programming of primary human T cells
MainEngineered T cells, containing transgenic T cell receptors (TCRs), chimeric antigen receptors (CARs) or other synthetic antigen receptors, are an emerging modality to treat cancer, autoimmunity and infectious diseases1,2,3,4. Although autologous CAR-T cells have been transformative for treating aggressive hematological malignancies, substantial advances are needed to achieve similar success in treating solid tumors and generating allogeneic cell therapies. Solid tumors demonstrate a number of challenges including immunosuppressive tumor microenvironments, physical barriers and T cell exhaustion that limit the responses of current therapies5,6,7. Allogeneic CAR-T cells must additionally overcome T cell rejection...
